That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from ...
The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
Providing feedback following point-of-care urine testing for tenofovir concentrations was associated with increased PrEP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback